top of page

Industry Expert in Japan with an MD


Patient-Centric Approach 


The Patientricity Way

Patient + Centricity = Patientricity

Helping biopharma transform

                       their business in Japan 

                                   one patient group at a time

We envision a society

           where no one patient gets left behind

Market Challenges

While Japan is recognized as being one of the most advanced healthcare systems in the world that offer universal coverage, there are many examples where innovation has been stifled and available treatment options are surprisingly limited, especially in rare diseases and certain cancer types. Unfortunately, some of these gaps are increasing, with the end result being that not everyone has equal access to the ideal treatments.

Patientricity aims to close the gap in patient access by making innovative medicines available to patients in Japan and helping patients have an improved quality of life. We believe that in order to close the gap between the ideal treatments and the realities of today, companies would benefit in taking a more patient-centric approach in identifying needs and designing solutions.

On Founding Patientricity

As a physician, I saw and treated patients on a daily basis. That changed when I started my ‘second’ career in the pharmaceutical industry, as I no longer had the chance to interact with patients.

Throughout my industry years, I observed firsthand situations where the needs of patients and

their families were not always fully understood by the company, which had to rely on an external

network of practicing physicians to glean related insights. In the process, I came to realize an

opportunity for me to help bridge that gap — and from this realization, Patientricity was born. 

If medicines (solutions) are developed to tackle diseases (issues) as intended, then it is essential

for pharmaceutical companies to listen to and talk with not only healthcare professionals, but also

with the very patients suffering from the ailments they seek to treat as well as their families.

I believe that better drug development and related services can only be achieved by incorporating

these understandings and the wishes of patients while ensuring they have a voice in this process

and are duly engaged.

In founding Patientricity, I have had the good fortune to resume my practice part-time; each week I now see roughly 25 patients with a variety of common diseases and disabilities, including hypertension, diabetes, chronic kidney diseases, common skin problems and dementia. In this dual capacity, my vision is to contribute to the transformation of the pharmaceutical industry in Japan toward an increasingly patient-centric model that not only engages patients better, but also serves them, and thereby society better.

_IGP1525 - コピー (3).JPG
bottom of page